Ophthalmological Research Foundation - Clinical Research Unit - Instituto Oftalmológico Fernández Vega

CLINICAL RESEARCH UNIT

Clinical research is the basic feature that allows medicines to be authorized with the guarantees required by law and ultimately to become part of clinical practice for the benefit of patients. It also allows new forms of use to be researched once the medicines are already commercialized. 


In short, clinical research enables the generation of high quality knowledge to develop therapeutic tools that improve those already available, and which contribute to the prevention, relief and cure of diseases and to the improvement of people´s quality of life.

Researcher:
Dr. Álvaro Fernández-Vega Sanz
Reclutando
Phase IV multicentre and single-group interventional study to evaluate a model for the treatment of and extension with intravitreal aflibercept for the treatment of secondary macular edema to the occlusion of the central retinal vein
Indication: Macular edema secondary to occlusion of the central
Treatment: Aflibercept
Promotor: Bayer AG
Researcher:
Dr. Álvaro Fernández-Vega Sanz
Reclutando
Treatment of age-related macular degeneration of the neovascular type (DMAEh) over 2 years with a treatment and extension model (T + E) of 2 mg aflibercept injected into the eye.
Indication: Patients with Macular Degeneration Associated with the Wet Age
Treatment: Aflibercept
Promotor: Bayer AG
Researcher:
Dr. Jesús Merayo Lloves
Reclutando
A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.
Indication: Moderate to severe dry eye
Treatment: Cyclosporine
Promotor: Mc2 biotec- Iris Pharma
Researcher:
Dr. Jesús Merayo Lloves
Reclutando
"Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye"
Indication: Patients with mild or moderate dry eye
Treatment: AVX-012
Promotor: Avizorex Pharma
Researcher:
Dr. Jesús Merayo Lloves
Reclutando
Efficacy and safety of T4020 versus its vehicle in patients with chronic neurotrophic keratitis or corneal ulcer.
Indication: atients with neurotrophic keratitis or neurotrophic corneal ulcer
Treatment: Cacicol®
Promotor: Laboratoires THÉA
Researcher:
Dr. Jesús Merayo Lloves
Reclutando
Double masked SYL1001 study in patients with moderate or severe dry eye disease
Indication: Patients with moderate to severe dry eye
Treatment: SYL1001
Promotor: SYLENTIS
Researcher:
Dr. Álvaro Fernández-Vega Sanz
Reclutando
Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC)
Indication: Patients with polypoid choroidal vasculopathy
Treatment: Aflibercept
Promotor: AIBILI
Cookies allow us to offer our services. By using our services, you agree to our use of cookies.